Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing

Early Relapse post Autologous Transplant is Associated With Very Poor Survival and Identifies an Ultra High Risk Group of Myeloma Patients

(2020) Efstathios Kastritis et al.   Clinical Lymphoma Myeloma & Leukemia

Multiple myeloma: 2020 update on diagnosis, risk‐stratification and management

(2020) S. Vincent Rajkumar   AMERICAN JOURNAL OF HEMATOLOGY

The future of myeloma precision medicine: integrating the compendium of known drug resistance mechanisms with emerging tumor profiling technologies

(2019) Taylor Harding et al.   LEUKEMIA

A Niche-Dependent Myeloid Transcriptome Signature Defines Dormant Myeloma Cells

(2019) Weng Hua Khoo et al.   BLOOD

Mitochondrial metabolism promotes adaptation to proteotoxic stress

(2019) Peter Tsvetkov et al.   Nature Chemical Biology

Single cell analyses of development in the modern era

(2019) Allon M. Klein et al.   DEVELOPMENT

Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance

(2019) Silpa Narayanan et al.   DRUG RESISTANCE UPDATES

Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk

(2019) Jill Corre et al.   HAEMATOLOGICA

Drug resistance in multiple myeloma

(2018) Pawel Robak et al.   CANCER TREATMENT REVIEWS

CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance

(2018) Niels W.C.J. van de Donk et al.   Frontiers in Immunology

Lung Single-Cell Signaling Interaction Map Reveals Basophil Role in Macrophage Imprinting

(2018) Merav Cohen et al.   CELL

Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma

(2018) Guy Ledergor et al.   NATURE MEDICINE

Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time

(2017) S K Kumar et al.   LEUKEMIA

Spatial reconstruction of immune niches by combining photoactivatable reporters and scRNA-seq

(2017) Chiara Medaglia et al.   SCIENCE

Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma

(2016) J. Krejcik et al.   BLOOD

Multiple myeloma and persistence of drug resistance in the age of novel drugs (Review)

(2016) SABNA RAJEEV KRISHNAN et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

(2016) Shaji Kumar et al.   LANCET ONCOLOGY

Primary failure of bortezomib in newly diagnosed multiple myeloma – understanding the magnitude, predictors, and significance

(2016) Yael C. Cohen et al.   LEUKEMIA & LYMPHOMA

Outcomes of primary refractory multiple myeloma and the impact of novel therapies

(2015) Neil Majithia et al.   AMERICAN JOURNAL OF HEMATOLOGY

Transcriptional Heterogeneity and Lineage Commitment in Myeloid Progenitors

(2015) Franziska Paul et al.   CELL

Molecular basis of resistance to proteasome inhibitors in hematological malignancies

(2015) Denise Niewerth et al.   DRUG RESISTANCE UPDATES

Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120)

(2015) R. Khan et al.   HAEMATOLOGICA

Molecular mechanisms in multiple myeloma drug resistance

(2015) Nicholas Nikesitch et al.   JOURNAL OF CLINICAL PATHOLOGY

Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120)

(2015) R. Khan et al.   HAEMATOLOGICA

Targeting the bone marrow microenvironment in multiple myeloma

(2014) Yawara Kawano et al.   IMMUNOLOGICAL REVIEWS

Massively Parallel Single-Cell RNA-Seq for Marker-Free Decomposition of Tissues into Cell Types

(2014) D. A. Jaitin et al.   SCIENCE

An Overview of Cyclophilins in Human Cancers

(2013) J Lee et al.   JOURNAL OF INTERNATIONAL MEDICAL RESEARCH

Endoplasmic Reticulum Stress and the Unfolded Protein Response: Targeting the Achilles Heel of Multiple Myeloma

(2013) L. Vincenz et al.   MOLECULAR CANCER THERAPEUTICS

Cyclophilin A: a key player for human disease

(2013) P Nigro et al.   Cell Death & Disease

Clonal competition with alternating dominance in multiple myeloma

(2012) J. J. Keats et al.   BLOOD

Clonal evolution in cancer

(2012) Mel Greaves et al.   NATURE

Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3

(2011) J. D. Shaughnessy et al.   BLOOD

Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1

(2011) S. C. W. Ling et al.   HAEMATOLOGICA

Multiple Myeloma

(2011) Antonio Palumbo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Treatment of relapsed and refractory multiple myeloma in the era of novel agents

(2010) Niels W.C.J. van de Donk et al.   CANCER TREATMENT REVIEWS

Prediction of Survival in Multiple Myeloma Based on Gene Expression Profiles Reveals Cell Cycle and Chromosomal Instability Signatures in High-Risk Patients and Hyperdiploid Signatures in Low-Risk Patients: A Study of the Intergroupe Francophone du Myélome

(2008) Olivier Decaux et al.   JOURNAL OF CLINICAL ONCOLOGY